Odyssey Therapeutics to Present Ulcerative Colitis Data at UEG Week
Odyssey Therapeutics will present additional Phase 2a induction data for its OD-001 drug in ulcerative colitis at UEG Week. The company will also host a conference call and webcast following the presentation.